National Lipid Association

Event

National Lipid Association Clinical Lipid Update 2020

presented by National Lipid Association

7 others would like to attend.

Register Now

Notification icon Friday, February 28, 2020 3 PM - Sunday, March 1, 2020 5 PM America/Los_Angeles

Location Icon 1750 Welton Street Denver, CO 80202

Event info

Register here

Save the Date for the National Lipid Association 2020 Spring Clinical Lipid Update, February 28 – March 1, 2020 at the Grand Hyatt Denver. The meeting will feature innovative topics in lipidology, the role of genetic testing in ASCVD Risk Assessment, the latest in pharmacotherapy for obesity and highlight the latest NLA position statement hot topics.

Featured topics include:

  • Updates on Evinacumab: ANGPTL3 and Lipid Management
  • Statin therapy in Older Primary Prevention Patients
  • Updates on Pharmacotherapy for Obesity

Earn up to 12 CME/CE credits and hear from renowned faculty while networking with some of the greatest minds in clinical lipidology. Stay at the top of your profession by registering now to attend this important event!

Educational Objectives:
At the conclusion of this activity, all participants should be able to:

  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team;

Session I- Drugs in the Pipeline

  • Discuss the role of novel therapies for the future clinical management of patients with dyslipidemia.

Session II: Fortune-Tellers and Crystal Balls in ASCVD: Divining and Refining Risk Assessment

  • Explain new refinements in the assessment of ASCVD risk in primary prevention patients.
  • Recognize challenges in classifying patient risk for ASCVD.
  • Summarize recent advancements in the use of genetics in primary prevention ASCVD risk assessment.

Session III:  One Size Does Not Fit All: Evidence-Based use of Statin Therapy in Special Populations

  • Discuss potential statin drug-drug interactions in special populations.
  • Describe the appropriate usage of statins in patients with chronic kidney disease.
  • Identify potential benefits and risks of statin use in the elderly.

Session IV: Improving Patient Outcomes in Statin Resistance and Intolerance

  • Summarize the evidence-based recommendations for current and emerging non-statin therapeutic interventions.
  • Demonstrate the potential use of non-statin therapies in an overall cardiovascular disease risk reduction management plan in patients not able to tolerate or resistant to statin therapy.

Session V: Weight Loss Strategies

  • Outline the impact of various diets on short-term and long-term weight loss.
  • Discuss pharmacologic therapy options for the treatment of obesity.

Session VI: The Journal of Clinical Lipidology Live Roundtable

  • Review the practical application of recent publications to the clinical evaluation and management of patients with dyslipidemia.

Session VII: Lifestyle and Diet Challenges

  • Compare and Contrast nutrition options in the management of patients with dyslipidemia.
  • Demonstrate counseling techniques for modifying diet and lifestyle.
  • Outline the impact of various diets on short-term and long-term cardiovascular risks.

Session VIII: Is the Rising Tide of Support for EPA Warranted or Just Another Fish-Tale?

  • Describe the evidence to support the benefit of omega-3 fatty acids.
  • Identify the recent clinical trial evidence for the use of omega 3 fatty acids in dyslipidemia management.
  • Discuss evidence that supports the benefits of nutritional supplements and dietary counseling in reducing cardiovascular disease.

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

7 others would like to attend.

Register Now


0 Comments
Login to view comments. Click here to Login